Full SIC benchmark · 21100
Manufacture of basic pharmaceutical products
A cohort-gated benchmark for this precise UK SIC classification. Use it as market context, then compare the parent industry by region or company size.
Performance profile
The measures available for this exact SIC
These are cohort averages, not a prediction for any single company or a substitute for checking an underlying company record.
| Measure | Benchmark | How to read it |
|---|---|---|
| Overall health score | 66 | Average benchmark score across the eligible cohort. |
| Profitability score | 41 | Derived 0–100 cohort signal where reported. |
| Gross margin | 65.6% | Average gross-margin signal where reported. |
| Revenue growth | 8.3% | Average growth signal; assess it alongside cohort size and risk. |
| Current ratio | 7.33 | Average liquidity ratio where reported. |
| Debt to equity | 7.22 | Average leverage ratio where reported. |
| Insolvency risk | 27 | Average risk signal; lower score is safer. This is not a credit decision. |